News Releases

‒ IDEAYA's inaugural Synthetic Lethality Investor Day is planned for April 20, 2021 with scientific presentations from IDEAYA and GSK scientific leaders, and several Key Opinion Leaders

- Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar®

‒ Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class MAT2A inhibitor for cancer patients harboring MTAP-deletion, which is prevalent in ~15% of all solid tumors

IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors

- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020

- The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program

- Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase

- Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share

- 4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines

- Dr. Garret Hampton serves as President, Clinical Sequencing and Oncology at Thermo Fisher Scientific, and held leadership roles at Illumina and Genentech

- Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs